alexa Molecular Recognition In Innovative Drug Design
ISSN: 2161-0444

Medicinal chemistry
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

3rd International Conference on Medicinal Chemistry & Computer Aided Drug Designing
December 08-10, 2014 DoubleTree by Hilton Hotel San Francisco Airport, USA

Patrick Y S Lam
Keynote: Med Chem
DOI: 10.4172/2161-0444.S1.010
Molecular recognition is the study of non-bonded interactions between molecules. This field has flourished in the past decades, generating numerous rules and restrictions which govern intermolecular interactions through supramolecular host/guest chemistry and macromolecular structural biology. Besides the three commonly-used classical interactions (hydrogen bonding, Coulombic interaction and hydrophobic interaction), there are numerous other interactions that have not been utilized in drug design. This review will highlight these novel interactions useful for innovative drug design. The author will also highlight the first successful utilization of halogen bonding in rational drug design. We successfully utilized the electro-positive tip of halogen to replace amidine to interact with the conserved electro-negative asp 189 of Factor Xa.
Patrick Y S Lam is currently an Adjunct Professor at Drexel University College of Medicine and Baruch S. Blumberg Institute. He is also a consultant at Lam Drug Discovery Consulting, LLC. He recently retired from a director position in the Discovery Chemistry Department of Bristol-Myers Squibb Co. He joined DuPont in 1984 and moved to BMS in 2001. He was the group leader/co-inventor responsible for the discovery of Eliquis?/Apixaban, a novel Factor Xa anticoagulant recently launched on the market.Patrick is also internationally known as the co-discoverer of the powerful Chan-Lam Coupling Reaction. He has authored 85 papers/ reviews/book chapters and is an inventor on 36 patents/patent applications. He received his PhD from the University of Rochester (Dr. Louis Friedrich) and was a postdoctoral fellow in UCLA (Prof. Mike Jung and the late Prof. Don Cram, 1987 Nobel Laureate).
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version